CAAR T Cells Targeting PR3-Reactive B Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for effectively targeting and eliminating disease-causing B cells in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), particularly those producing autoantibodies against proteinase 3 (PR3).
Innovation Solution
Development of chimeric autoantibody receptor (CAAR) T cells equipped with an extracellular PR3 antibody binding domain, a transmembrane region, and an intracellular signaling region, allowing for specific targeting and elimination of PR3-reactive B cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to target B cells, then treatment is administered, but effectiveness in eliminating PR3-reactive B cells is insufficient
Solution Approach 1:
The patent introduces chimeric autoantibody receptors (CAARs) as intermediary molecules on T cell surfaces that specifically recognize and bind to PR3-reactive B cells through their anti-PR3 autoantibodies. This intermediary mechanism enables targeted engagement between T cells and disease-causing B cells, improving both reliability and productivity of B cell elimination compared to conventional non-specific methods
Solution Approach 2:
The patent replaces conventional non-specific immunosuppressive mechanisms with a specific biological recognition system. The CAAR structure substitutes general immune suppression with targeted molecular recognition, where the extracellular domain of the CAAR binds specifically to PR3 epitopes on autoantibodies, enabling precise elimination of pathogenic B cells while preserving other immune functions
2Measurement precision
If CAAR T cells are developed with specific PR3 binding domain, then specificity for PR3-reactive B cells is improved, but device complexity increases
Solution Approach 1:
The CAAR is segmented into distinct functional domains: an extracellular PR3 antibody binding domain (derived from PR3 protein or antibody fragments), a transmembrane region, and an intracellular signaling region. This segmentation allows each domain to be optimized independently - the extracellular domain provides specific PR3 recognition while the intracellular domain delivers targeted signaling, achieving high specificity without requiring complete redesign of the entire T cell system
Solution Approach 2:
The CAAR structure serves multiple functions simultaneously: the extracellular domain provides specific PR3 epitope recognition, the transmembrane region anchors the receptor in the cell membrane, and the intracellular domain mediates signal transduction for B cell elimination. This multi-functionality in a single molecular construct achieves high specificity while managing structural complexity through functional integration
Data Source
AI summary
Provided herein are cell and protein therapeutics that comprise a Proteinase 3 (PR3) antibody binding domain, such as a wild type PR3 protein or mutant PR3 protein, and methods of use thereof. Also provided herein arc chimeric autoantibody receptors (CAARs) comprising an extracellular PR3 antibody binding domain. Among the provided CAARs are those in which the extracellular PR3 antibody binding domain ia a wild type or mutated PR3 protein or fragment thereof that are able to be specifically bound by an anti-PR3 antineutrophil cytoplasmic antibody (ANCA). Also provided herein are polynucleotides that encode the provided CAARs, genetically engineered cells such as T cells containing the provided CAARs, and to related methods and uses thereof in adoptive cell therapy.